Daily Endocrinology Research Analysis
Analyzed 120 papers and selected 3 impactful papers.
Summary
Analyzed 120 papers and selected 3 impactful articles.
Selected Articles
1. American Thyroid Association 2026 Guidelines for Thyroid Disease in Preconception, Pregnancy, and Postpartum.
This multidisciplinary, GRADE-based ATA guideline updates evidence-based recommendations for thyroid disease across preconception, pregnancy, and postpartum, covering testing, iodine, autoimmunity, hypo-/hyperthyroidism (including Graves’), nodules/cancer, and postpartum dysfunction. It synthesizes new evidence since 2017 into pragmatic tables and considerations to support individualized care.
Impact: Guidelines directly shape clinical practice for a common and high-stakes population, offering consensus-based, implementable recommendations with immediate relevance.
Clinical Implications: Provides standardized, GRADE-aligned care pathways for screening, diagnosis, and management of thyroid conditions in reproductive settings, facilitating consistent decision-making, patient counseling, and multidisciplinary coordination.
Key Findings
- Delivers updated, evidence-based recommendations for thyroid testing, iodine supplementation, autoimmunity, hypo-/hyperthyroidism (including Graves’ disease), thyroid nodules/cancer, and postpartum thyroid dysfunction.
- Uses systematic searches and GRADE to balance benefits/harms, patient values, feasibility, and equity; includes Good Practice Statements where evidence is limited.
- Provides pragmatic recommendation tables, boxed practical considerations, and background context across conditions and timepoints (preconception, pregnancy, postpartum).
Methodological Strengths
- Systematic literature review with GRADE framework across multi-society task force
- Explicit incorporation of patient values, feasibility, and equity; practical recommendation tables
Limitations
- Many topics rely on low-to-moderate quality evidence acknowledged by the authors
- Heterogeneity across conditions may limit specificity of some recommendations
Future Directions: Prospective validation of key recommendations, real-world implementation studies, and targeted trials to close evidence gaps in pregnancy-related thyroid care.
BACKGROUND: Thyroid disease in pregnancy, preconception, and postpartum is a common and clinically relevant problem. Since the publication of the American Thyroid Association (ATA) guidelines in 2017, substantial new clinical and scientific evidence has become available. The aim of these guidelines is to provide clinicians, patients, researchers, and policymakers with evidence-based recommendations on the care of women with thyroid disease before, during, and after pregnancy. METHODS: The clinical questions addressed were informed by prior ATA guidelines, stakeholder feedback, a global needs assessment, and input from the multidisciplinary task force. Systematic literature searches were conducted with the support from a medical librarian and evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation framework. Recommendations were formulated based on the quality of evidence, balance of benefits and harms, patient values, feasibility, and equity. Where data were limited, Good Practice Statements were formulated. The task force included representatives from 10 international societies as well as patient advocacy groups and a methodologist. RESULTS: The updated guidelines include recommendations on thyroid function testing, iodine supplementation, thyroid autoimmunity, hypothyroidism, hypothyroxinemia, hyperthyroidism and Graves' disease, thyroid nodules and cancer, and postpartum thyroid dysfunction for women with infertility, pregnant women, and women during postpartum and/or lactation. Recommendations are presented using recommendation tables, additional practical considerations are highlighted in boxes, and background information is provided in the text, tables, and figures per disease entity and chronological subset. CONCLUSIONS: These 2026 ATA guidelines provide updated, evidence-based recommendations for the diagnosis and management of thyroid disease in women during preconception, pregnancy, and postpartum. While acknowledging that much of the evidence remains of low-to-moderate quality, these guidelines represent current best practices and consensus among international experts from different fields, offering an optimized framework for individualized patient care.
2. The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis.
Across 97,173 participants in 15 RCTs, GLP-1–based therapies reduced all-cause and cardiovascular mortality and MACE in pairwise analyses. Network meta-analysis suggested agent-level differences for MACE favoring efpeglenatide, albiglutide, and injectable semaglutide, with albiglutide reducing non-fatal MI versus placebo; stroke estimates were imprecise.
Impact: Provides contemporary, agent-level comparative cardiovascular estimates for GLP-1 therapies, informing nuanced drug selection in T2D beyond class effects.
Clinical Implications: Reinforces class-level CV benefit of GLP-1–based therapies and suggests potential agent-level differentiation for MACE, guiding individualized therapy selection in high CV-risk T2D.
Key Findings
- Pairwise meta-analyses showed significant reductions in all-cause mortality, cardiovascular mortality, and MACE with GLP-1–based therapies versus placebo.
- In the network meta-analysis, efpeglenatide, albiglutide, and injectable semaglutide had the most favorable MACE profiles.
- Albiglutide reduced non-fatal myocardial infarction versus placebo; non-fatal stroke estimates were imprecise.
Methodological Strengths
- Inclusion of randomized controlled trials with hazard ratio–based synthesis
- Frequentist random-effects network meta-analysis enabling agent-level comparisons
Limitations
- Indirect comparisons limit causal inference on between-agent differences
- Imprecise estimates for some outcomes (e.g., non-fatal stroke)
Future Directions: Head-to-head cardiovascular outcome trials and real-world comparative effectiveness studies to validate agent-level differences and optimize patient selection.
AIMS: To provide updated agent-level comparative estimates of GLP-1-based therapies for cardiovascular outcomes in adults with Type 2 diabetes mellitus (T2DM) using a hazard ratio (HR)-based systematic review and network meta-analysis (NMA). METHODS: PubMed, Cochrane Library and Scopus were searched through December 2025 for randomized controlled trials evaluating GLP-1-based therapies in adults with T2DM and reporting time-to-event cardiovascular outcomes. Pairwise meta-analyses and a frequentist random-effects NMA were performed for all-cause mortality, cardiovascular mortality, major adverse cardiovascular events (MACE), non-fatal myocardial infarction (MI) and non-fatal stroke. RESULTS: Fifteen trials involving 97,173 participants were included. In pairwise placebo-controlled analyses, GLP-1-based therapies significantly reduced all-cause mortality, cardiovascular mortality and MACE. In the NMA, mortality estimates for several agents favoured benefit, although most comparisons were not statistically significant. For MACE, efpeglenatide, albiglutide and injectable semaglutide showed the most favourable comparative profiles. Albiglutide reduced non-fatal MI versus placebo, whereas non-fatal stroke estimates were imprecise. CONCLUSIONS: GLP-1-based therapies were associated with an overall favourable cardiovascular profile in T2DM. Pairwise analyses supported class-level benefit, whereas between-agent differences were more evident for MACE than for mortality outcomes in the NMA.
3. Coordinated expression and assembly of BiP, p58
Using a genetically engineered mouse that enables specific pulldown of endogenous β-cell BiP (GRP78) complexes, the study shows that BiP assembles into diverse chaperone complexes (including with cochaperones such as p58) that coordinate proinsulin folding. These data mechanistically link coordinated ER chaperone assemblies to protection against proinsulin misfolding and β-cell ER stress relevant to T2D.
Impact: Introduces a powerful in vivo tool to map ER chaperone–client interactions in β cells and reveals coordinated BiP-centered complexes critical for proinsulin proteostasis.
Clinical Implications: While preclinical, delineating BiP-centered chaperone coordination informs therapeutic strategies targeting β-cell ER proteostasis to preserve insulin production in T2D.
Key Findings
- Developed a genetically engineered mouse enabling efficient, specific pulldown of endogenous islet β-cell BiP (GRP78) in complex with client proteins.
- Demonstrated that BiP assembles into diverse protein complexes, including with cochaperones such as p58, coordinating proinsulin folding.
- Mechanistically links ER chaperone coordination to prevention of proinsulin misfolding and β-cell ER stress relevant to T2D pathophysiology.
Methodological Strengths
- Innovative genetically engineered mouse enabling endogenous BiP interactome capture in β cells
- In vivo complex pulldown allows physiologic mapping of ER chaperone coordination
Limitations
- Preclinical mechanistic study without direct human validation
- Abstract truncation limits detailed insight into all identified cochaperone partners and pathways
Future Directions: Translate findings to human islets, define full BiP interactome under metabolic stress, and test pharmacologic modulation of BiP complexes to improve β-cell proteostasis.
Proper proinsulin folding in the endoplasmic reticulum (ER) is prerequisite to producing bioactive insulin, and proinsulin misfolding causing β cell ER stress accompanies pancreatic β cell dysfunction in type 2 diabetes (T2D). How (and which) ER chaperones coordinate to prevent proinsulin misfolding is largely unknown other than an unspecified dependence on the hsp70 member, BiP. A genetically engineered mouse enables efficient, specific pulldown of endogenous islet β cell BiP (GRP78, the major HSP70 ER chaperone) in complexes with client proteins. We demonstrate that BiP assembles in various protein complexes (including cochaperones p58